BioRestorative Therapies Statistics
Share Statistics
BioRestorative Therapies has 6.92M shares outstanding. The number of shares has increased by 47.02% in one year.
| Shares Outstanding | 6.92M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 5.08M |
| Failed to Deliver (FTD) Shares | 2.46K |
| FTD / Avg. Volume | 4.39% |
Short Selling Information
The latest short interest is 153.38K, so 2.22% of the outstanding shares have been sold short.
| Short Interest | 153.38K |
| Short % of Shares Out | 2.22% |
| Short % of Float | 3.02% |
| Short Ratio (days to cover) | 1.59 |
Valuation Ratios
The PE ratio is -0.7 and the forward PE ratio is -0.96.
| PE Ratio | -0.7 |
| Forward PE | -0.96 |
| PS Ratio | 50.33 |
| Forward PS | 4 |
| PB Ratio | 0.73 |
| P/FCF Ratio | -1.11 |
| PEG Ratio | n/a |
Enterprise Valuation
BioRestorative Therapies Inc. has an Enterprise Value (EV) of 6.62M.
| EV / Earnings | -0.64 |
| EV / Sales | 45.39 |
| EV / EBITDA | -0.44 |
| EV / EBIT | -0.43 |
| EV / FCF | -1 |
Financial Position
The company has a current ratio of 4.37, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.37 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.6 |
| Cash Flow / Debt | -39.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.04% and return on capital (ROIC) is -149.71%.
| Return on Equity (ROE) | -1.04% |
| Return on Assets (ROA) | -0.83% |
| Return on Capital (ROIC) | -149.71% |
| Revenue Per Employee | 13.25K |
| Profits Per Employee | -947.06K |
| Employee Count | 11 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 11.18% in the last 52 weeks. The beta is 62.82, so BioRestorative Therapies 's price volatility has been higher than the market average.
| Beta | 62.82 |
| 52-Week Price Change | 11.18% |
| 50-Day Moving Average | 1.52 |
| 200-Day Moving Average | 1.55 |
| Relative Strength Index (RSI) | 63.47 |
| Average Volume (20 Days) | 56.02K |
Income Statement
In the last 12 months, BioRestorative Therapies had revenue of 145.80K and earned -10.42M in profits. Earnings per share was -2.47.
| Revenue | 145.80K |
| Gross Profit | 145.80K |
| Operating Income | -15.22M |
| Net Income | -10.42M |
| EBITDA | -15.06M |
| EBIT | -15.22M |
| Earnings Per Share (EPS) | -2.47 |
Balance Sheet
The company has 884.38K in cash and 162.32K in debt, giving a net cash position of 722.06K.
| Cash & Cash Equivalents | 884.38K |
| Total Debt | 162.32K |
| Net Cash | 722.06K |
| Retained Earnings | -146.70M |
| Total Assets | 14.57M |
| Working Capital | 8.93M |
Cash Flow
In the last 12 months, operating cash flow was -6.43M and capital expenditures -171.04K, giving a free cash flow of -6.60M.
| Operating Cash Flow | -6.43M |
| Capital Expenditures | -171.04K |
| Free Cash Flow | -6.60M |
| FCF Per Share | -1.57 |
Margins
Gross margin is 100%, with operating and profit margins of -10.44K% and -7.15K%.
| Gross Margin | 100% |
| Operating Margin | -10.44K% |
| Pretax Margin | -7.15K% |
| Profit Margin | -7.15K% |
| EBITDA Margin | -10.33K% |
| EBIT Margin | -10.44K% |
| FCF Margin | -4.53K% |
Dividends & Yields
BRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -137.99% |
| FCF Yield | -53.14% |
Analyst Forecast
The average price target for BRTX is $18, which is 905.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $18 |
| Price Target Difference | 905.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 27, 2021. It was a backward split with a ratio of 1:4000.
| Last Split Date | Oct 27, 2021 |
| Split Type | backward |
| Split Ratio | 1:4000 |
Scores
| Altman Z-Score | -15.41 |
| Piotroski F-Score | 2 |